Trial reportJournal of magnetic resonance imaging : JMRI2026
Assessing Quality and Adherence to PI-RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG-GU005.
Trial report in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03367702 (Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Who cites it
2 citing papers in PubMed.
- Assessing Quality and Adherence to PI-RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG-GU005.Journal of magnetic resonance imaging : JMRI · 2026Trial
- Impact of central review and MRI image quality on prostate cancer diagnosis and biopsy decision-making in referred patients.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundMulti-parametric MRI (mpMRI) datasets often vary between sites due to differences in acquisition protocols. PURPOSE: Evaluate adherence of multi-site mpMRI dataset to minimum technical standards (MTS) of PI-RADSv2.1. STUDY TYPE: Prospective. SUBJECTS: Six hundred patients (Age (years): ≤ 49 = 0.8%, 50-59 = 10.7%, 60-69 = 47.0%, ≥ 70 = 41.5%) with intermediate-risk prostate cancer (PCa) imaged across 124 institutions prior to radiotherapy. FIELD STRENGTH/SEQUENCE: 3T, 1.5T, and 1.16T, T2-weighted (T2w): fast spin-echo, diffusion-weighted imaging (DWI): single-shot echo-planar imaging, and dynamic contrast-enhanced (DCE): T1-weighted 3D fast spoiled gradient echo. ASSESSMENT: Scanner vendors included Siemens, GE, Philips, Toshiba, and Hitachi. Degree of adherence to PIRADSv2.1 was determined as the proportion of datasets that met MTS. Mean and standard deviation of parameter values were calculated where applicable. Prostate imaging quality (PI-QUAL)v2 scores were assigned by one of three observers in 491 datasets. Evaluation of DICOM metadata consistency was performed. STATISTICAL TESTS: Fisher's exact test to assess changes in MTS adherence over time and by field strength; Harrel's C-index to compare MTS adherence to PI-QUAL score. A p value of < 0.001 is considered statistically significant after Bonferroni correction.
resultsEighty-two percent of MTS showed greater than 75% adherence. Low adherence was found in the in-plane dimension (frequency-encoding direction) for T2w images (57%, mean = 0.45 ± 0.16 mm) and field of view (FOV) for DW images (62%, mean = 22.67 ± 4.70 cm). Only 50% of datasets used the recommended high b value image to compute the apparent diffusion coefficient map. Adherence improved significantly over time for one T2w and two DWI parameters; the adherence of FOV improved significantly at 3T for T2w and DWI sequences. C-index values for two T2w and two DWI parameters demonstrated a relationship between PI-RADS MTS and PI-QUAL score. Ten percent of anonymized datasets were stripped of some sequence information. DATA
conclusionResults show promise for mpMRI standardization in characterization of PCa and identify key parameters that remain variable across datasets and institutions. EVIDENCE LEVEL: 1. TECHNICAL EFFICACY: Stage 2.
trial registrationClinicalTrials.gov: NCT03367702.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.